Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus
|ClinicalTrials.gov Identifier: NCT00407069|
Recruitment Status : Completed
First Posted : December 4, 2006
Last Update Posted : October 18, 2016
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||286 participants|
|Observational Model:||Case Control|
|Official Title:||Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus (ADVN AMP01)|
|Study Start Date :||June 2005|
|Primary Completion Date :||February 2010|
|Study Completion Date :||February 2010|
Active Atopic Dermatitis (AD)
Pediatric and adult subjects who fulfill the criteria for AD, a chronic inflammatory skin disease.
Inactive Atopic Dermatitis (AD)
Adult subjects with a prior history of active AD that has been quiescent for at least 1 year.
Adult subjects who fulfill the criteria for plaque psoriasis, a chronic inflammatory skin disease.
Asthmatics (without a history of AD)
Adult subjects who fulfill the criteria for asthma (reactive airway disease) and have a negative history of skin disease.
Eczema Herpeticum (EH
Pediatric and adult AD subjects with a history of EH.
Healthy individuals with no history of skin or respiratory disease.
- Expression of vaccinia virus mRNA in non-lesional skin following inoculation with untreated vaccinia virus will be evaluated using real-time RT-PCR (Reverse transcription polymerase chain reaction). [ Time Frame: 5 years ]
- Expression of cytokines, AMPs, other antiviral molecules, or epidermal differentiation proteins in non-lesional skin prior to and after inoculation with vaccinia virus will be evaluated using real-time RT-PCR. [ Time Frame: 5 years ]
- Keratinocytes will be stimulated with vaccinia virus in the presence and absence of Th1 or Th2 cytokines. Non-lesional AD skin will be stimulated with vaccinia virus in the presence of antibodies that neutralize Th2 cytokines. [ Time Frame: 5 years ]
- Vaccinia virus replication will be evaluated using a standard viral plaque assay in BS-C-1 cells and by analyzing vaccinia virus mRNA expression using real-time RT-PCR in keratinocytes and BS-C-1 cells. [ Time Frame: 5 years ]
- Expression of over 20,000 genes will be evaluated by GeneChip microarrays in non-lesional skin, and PBMCs stimulated with vaccinia virus. Real-time RT-PCR of skin and PBMC will be used to confirm gene alterations found in GeneChip microarrays. [ Time Frame: 5 years ]
- Ability of structural analogues of CSAs (Cyclosporine) to kill purified vaccinia virus as well as keratinocytes infected with vaccinia virus in vitro. [ Time Frame: 5 years ]
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00407069
|United States, Colorado|
|National Jewish Health|
|Denver, Colorado, United States, 80207|
|Principal Investigator:||Donald Leung, MD, PhD||National Jewish Health|